1. Academic Validation
  2. High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY191704, a human type 1 5 alpha-reductase inhibitor, in plasma

High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY191704, a human type 1 5 alpha-reductase inhibitor, in plasma

  • J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):212-6. doi: 10.1016/s0378-4347(96)00383-0.
N A Farid 1 N L Coleman
Affiliations

Affiliation

  • 1 Division of Drug Metabolism and Disposition, Lilly Research Laboratories, Lilly Corporate Center, Indianpolis, IN 46285, USA.
Abstract

A stereoselective reversed-phase liquid chromatographic method for the determination of compounds LY300502 and LY300503 (enantiomers of LY191704) in rat and dog plasma was developed. The assay involved extraction of the compounds using a strong cation-exchange solid-phase extraction column, from which the compounds are eluted with 1% of 1 M HCI in methanol. The enantiomers were separated on a Daicel Chiralcel OD-R column. The mobile phase consisted of water-acetonitrile-methanol (50:40:10, v/v) at a flow-rate of 0.3 ml/min. UV detection was achieved at 220 nm. The disposition of the enantiomers of LY191704 in rats and dogs was found to be stereoselective and species specific.

Figures
Products